Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof
View Patent ↗Severe Acute Respiratory Syndrome (“SARS”) is a human respiratory disease of recent origin, widespread infectivity, recurring incidence, and significant mortality. Although there is abundant evidence suggesting that the coronavirus responsible for the disease (“SARS-CoV”) evolves during an outbreak, there is currently little data on the earliest strains of this coronavirus. The present invention is directed to the characterization of the genomic RNA sequences of these earliest SARS coronaviruses, to the identification of nucleotide positions within the SARS-CoV genomic RNA that are characteristic of the different evolutionary stages of the coronavirus, to kits based on these positions for use in diagnosis of the disease in patients, and for the development of vaccines to the disease based on the lowered virulence and contagiousness of these earliest strains of SARS-CoV.
1. A method for detecting an early-stage SARS coronavirus comprising:
providing a sample suspected of containing the early stage SARS coronavirus; and
identifying the presence of at least one early-stage-specific molecular marker in a viral RNA, using a protocol comprising preparing coronaviral RNA from the sample, and obtaining cDNA using reverse transcription,
wherein the early-stage-specific molecular marker is selected from the group consisting of: an insertion early-stage-specific molecular marker, a deletion early-stage-specific molecular marker, and at least one single nucleotide variation (SNV) early-stage-specific molecular marker, wherein the SNV early-stage-specific molecular marker is C at position 4220.
2. A method for detecting an early-stage SARS coronavirus comprising:
providing a sample suspected of containing the early stage SARS coronavirus, and
identifying the presence of at least one early-stage-specific molecular marker in a viral RNA, using a protocol comprising preparing coronaviral RNA from the sample, and obtaining cDNA using reverse transcription,
wherein the early-stage-specific molecular marker is selected from the group consisting of: an insertion early-stage-specific molecular marker, a deletion early-stage-specific molecular marker, and at least one single nucleotide variation (SNV) early-stage-specific molecular marker, wherein the at least one SNV is selected from the group of molecular markers consisting of C at position 4220 and C at position 23823.
3. The method of claim 2 , wherein the SNV early-stage-specific molecular marker is C at position 4220.
4. A method for detecting an early-stage SARS coronavirus in a patient comprising: obtaining a sample from the patient suspected of containing an early-stage SARS coronavirus;
isolating viral RNA and obtaining cDNA by reverse transcription,
determining the nucleotide present at the position corresponding to 4220 in SEQ ID NO: 1, wherein the presence of the nucleotide C at the position indicates an early-stage SARS coronavirus.
5. A method for detecting an early-stage SARS coronavirus comprising:
obtaining a sample from the patient suspected of containing an early-stage SARS coronavirus;
isolating viral RNA and obtaining cDNA by reverse transcription,
determining the nucleotide present at the positions corresponding to 4220 and 23823 in SEQ ID NO: 1, wherein the presence of the nucleotide C at the positions indicates an early-stage SARS coronavirus.
6. The method of claim 5 , wherein the presence of the nucleotide C at position 4220 indicates an early-stage SARS coronavirus.